Evgeniy Vasilievich Papichev
Research Subjects
Evgeniy Vasilievich Papichev has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Yulia Vasilievna Polyakova
Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky
31 shared publications - Larisa Evgenievna Sivordova
Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky
30 shared publications - Boris Valerievich Zavodovsky
Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky
29 shared publications - Yuri Rubenovich Akhverdyan
Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky
28 shared publications Ю. Р. Ахвердян
Научно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. Зборовского
17 shared publicationsЮ. В. Полякова
Научно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. Зборовского
13 shared publications
Latest Publications
- 15 November 2026
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 28 (4) , 879-890
TNF-associated apoptosis-inducing ligand in patients with rheumatic diseases
Impaired immune tolerance and dysregulation of programmed cell death pathways are central mechanisms inpathogenesis of autoimmunerheumaticdiseases. Tumor necrosis factor (TNF)-relatedapoptosisinducing ligand (TRAIL) is an important immunoregulatory molecule involved in elimination of autoreactive lymphocytes and modulation of innate and adaptive immune responses. In addition to its proapoptotic activity, this ligand may activate non-apoptotic signaling pathways associated with cytokine production, cell survival, and chronic inflammation. However, its contribution to immune dysregulation in rheumatic diseases remains poorly studied. The objective of the present work was to evaluate serum levels of TRAIL in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS), and to investigate its associations with clinical and immunological disease characteristics. This pilot study included 73 participants: 18 patients with RA, 29 with SLE, 16 with AS, and 9 healthy controls. Serum levels of TRAIL were measured by ELISA technique. Immunological testing included determination of rheumatoid factor, antibodies to cyclic citrullinated peptides, antibodies to double-stranded DNA, and serum complement components. Statistical evaluation included comparative, correlation, and receiver operating characteristic curve analyses. Patients with RA exhibited significantly elevated serum levels of TRAIL compared with healthy controls and patients with SLE or AS. A trend toward higher concentrations was observed in antibody-positive rheumatoid arthritis, suggesting a relationship between this mediator and autoimmune activation. In SLE, increased ligand levels were associated with joint involvement, potentially reflecting enhanced type I interferon-driven immune activation. ROC analysis demonstrated high diagnostic performance of the biomarker for identifying RA. Elevated serum levels of TRAIL are associated with RA and may reflect disturbances in apoptosis-mediated immune regulation and persistence of autoimmune inflammation. These findings support the involvement of this mediator in immunopathogenesis of rheumatic diseases and highlight its potential utility as a component of immunological biomarker panels for rheumatoid arthritis.
- 15 November 2026
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 28 (4) , 879-890
TNF-associated apoptosis-inducing ligand in patients with rheumatic diseases
Impaired immune tolerance and dysregulation of programmed cell death pathways are central mechanisms inpathogenesis of autoimmunerheumaticdiseases. Tumor necrosis factor (TNF)-relatedapoptosisinducing ligand (TRAIL) is an important immunoregulatory molecule involved in elimination of autoreactive lymphocytes and modulation of innate and adaptive immune responses. In addition to its proapoptotic activity, this ligand may activate non-apoptotic signaling pathways associated with cytokine production, cell survival, and chronic inflammation. However, its contribution to immune dysregulation in rheumatic diseases remains poorly studied. The objective of the present work was to evaluate serum levels of TRAIL in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS), and to investigate its associations with clinical and immunological disease characteristics. This pilot study included 73 participants: 18 patients with RA, 29 with SLE, 16 with AS, and 9 healthy controls. Serum levels of TRAIL were measured by ELISA technique. Immunological testing included determination of rheumatoid factor, antibodies to cyclic citrullinated peptides, antibodies to double-stranded DNA, and serum complement components. Statistical evaluation included comparative, correlation, and receiver operating characteristic curve analyses. Patients with RA exhibited significantly elevated serum levels of TRAIL compared with healthy controls and patients with SLE or AS. A trend toward higher concentrations was observed in antibody-positive rheumatoid arthritis, suggesting a relationship between this mediator and autoimmune activation. In SLE, increased ligand levels were associated with joint involvement, potentially reflecting enhanced type I interferon-driven immune activation. ROC analysis demonstrated high diagnostic performance of the biomarker for identifying RA. Elevated serum levels of TRAIL are associated with RA and may reflect disturbances in apoptosis-mediated immune regulation and persistence of autoimmune inflammation. These findings support the involvement of this mediator in immunopathogenesis of rheumatic diseases and highlight its potential utility as a component of immunological biomarker panels for rheumatoid arthritis.
- Open Access
- 14 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 173-181
Clinical and pathogenetic significance of monocyte chemotactic protein-1 in rheumatoid arthritis: A literature review
Monocyte chemotactic protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), plays a key role in regulating inflammation in various pathologies. It is directly or indirectly implicated in the pathogenesis of oncologic and pulmonary diseases, neuroinflammatory, cardiovascular, and skin diseases. Its role as a biomarker of disease severity has been proven. The role of this chemokine in the pathogenesis of immune-mediated inflammatory rheumatic diseases remains insufficiently studied and is of considerable scientific interest. The aim of this literature review was to analyze scientific data on the pathogenetic role of MCP-1 in rheumatoid arthritis (RA) and the prospects for its use in clinical practice. A search for scientific publications was performed in the electronic databases PubMed, Google Scholar, and eLIBRARY.RU, published in Russian and English before February 2026. This review of the scientific literature clarified the role of MCP-1 in the pathogenesis of RA and highlighted one of the most pressing areas of scientific research: the development of new drugs (antagonists of the receptor of this chemokine, CCR2). MCP-1 has been shown to play a key role in enhancing the inflammatory cascade and is closely associated with chronic, uncontrolled inflammation. MCP-1 exerts its biological effects on migration, infiltration, and differentiation of immune cells by binding to its receptor, CCR2. The MCP-1 (CCL2)/CCR2 axis is a central inflammatory mechanism that attracts monocytes to the site of inflammation. Currently, proposed CCR2 antagonist drugs are not sufficiently effective, and extrapolation of experimental results in animal models does not justify clinical trials. Nevertheless, the development of new CCR2 antagonists and/or their combination with other immunomodulators may be a promising strategy for improving the effectiveness of RA treatment.
- 14 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 173-181
Open AccessClinical and pathogenetic significance of monocyte chemotactic protein-1 in rheumatoid arthritis: A literature review
Monocyte chemotactic protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), plays a key role in regulating inflammation in various pathologies. It is directly or indirectly implicated in the pathogenesis of oncologic and pulmonary diseases, neuroinflammatory, cardiovascular, and skin diseases. Its role as a biomarker of disease severity has been proven. The role of this chemokine in the pathogenesis of immune-mediated inflammatory rheumatic diseases remains insufficiently studied and is of considerable scientific interest. The aim of this literature review was to analyze scientific data on the pathogenetic role of MCP-1 in rheumatoid arthritis (RA) and the prospects for its use in clinical practice. A search for scientific publications was performed in the electronic databases PubMed, Google Scholar, and eLIBRARY.RU, published in Russian and English before February 2026. This review of the scientific literature clarified the role of MCP-1 in the pathogenesis of RA and highlighted one of the most pressing areas of scientific research: the development of new drugs (antagonists of the receptor of this chemokine, CCR2). MCP-1 has been shown to play a key role in enhancing the inflammatory cascade and is closely associated with chronic, uncontrolled inflammation. MCP-1 exerts its biological effects on migration, infiltration, and differentiation of immune cells by binding to its receptor, CCR2. The MCP-1 (CCL2)/CCR2 axis is a central inflammatory mechanism that attracts monocytes to the site of inflammation. Currently, proposed CCR2 antagonist drugs are not sufficiently effective, and extrapolation of experimental results in animal models does not justify clinical trials. Nevertheless, the development of new CCR2 antagonists and/or their combination with other immunomodulators may be a promising strategy for improving the effectiveness of RA treatment.
- Open Access
- 21 June 2026
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 2,p. 15-18
Laboratory assessment of bone metabolism parameters by determining serum C-terminal type I collagen telopeptides in patients with rheumatoid arthritis
The aim of the study was to investigate the relationship between the serum level of C-terminal telopeptides of type I collagen and clinical and laboratory features of rheumatoid arthritis in elderly female patients. We observed 87 patients with a reliable diagnosis of RA. The average age of the patients was 67.4±6.9 (61.7-73.4) years. The duration of RA ranged from 0.2 to 33 years (9 [4-16]). The average level of β-Cross Laps in patients with RA was 0.684 [0.40-0.78] ng/ml, an increase in the upper limit of the norm was observed in 28 (32.2%) patients. No significant relationship was found between the level of β-Cross Laps and age, as well as height, weight and BMI of the patients. A relationship was found between the concentration of β-Cross Laps and disease activity (K-W χ2=3.318, p=0.042), radiographic stage (K-W χ2=2.960, p=0.036), functional class (K-W χ2=3.639, p=0.030) and CRP level (ρ=3.1907; p= 0.037).
- 21 June 2026
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 2,p. 15-18
Open AccessLaboratory assessment of bone metabolism parameters by determining serum C-terminal type I collagen telopeptides in patients with rheumatoid arthritis
The aim of the study was to investigate the relationship between the serum level of C-terminal telopeptides of type I collagen and clinical and laboratory features of rheumatoid arthritis in elderly female patients. We observed 87 patients with a reliable diagnosis of RA. The average age of the patients was 67.4±6.9 (61.7-73.4) years. The duration of RA ranged from 0.2 to 33 years (9 [4-16]). The average level of β-Cross Laps in patients with RA was 0.684 [0.40-0.78] ng/ml, an increase in the upper limit of the norm was observed in 28 (32.2%) patients. No significant relationship was found between the level of β-Cross Laps and age, as well as height, weight and BMI of the patients. A relationship was found between the concentration of β-Cross Laps and disease activity (K-W χ2=3.318, p=0.042), radiographic stage (K-W χ2=2.960, p=0.036), functional class (K-W χ2=3.639, p=0.030) and CRP level (ρ=3.1907; p= 0.037).
- Open Access
- 5 October 2025
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 40 (3) , 28-35
The value of fibroblast growth factor 21 in health and pathology
The article presents current ideas about the role of fibroblast growth factor 21 (FGF21) in the regulation of carbohydrate and lipid metabolism, as well as its contribution to the development of systemic inflammation in rheumatoid arthritis, both in laboratory animals and in humans. The classification of the fibroblast growth factor family, regulation of expression and receptor apparatus is considered. Positive effects of FGF21 have been noted in the form of normalization of carbohydrate and lipid metabolism, body weight; drugs analogues of FGF21 have proven themselves well as a therapeutic agent for the treatment of metabolic complications such as diabetes and fatty liver disease. At the same time, data are provided on the connection between elevated levels of FGF21 in blood serum and a number of pathological conditions, such as type 2 diabetes mellitus, coronary heart disease, obesity, non-alcoholic fatty liver disease, and end-stage renal failure. The facts about the controversial role of FGF21 against the background of systemic inflammation in patients with rheumatoid arthritis (RA) are reviewed. On the one hand, FGF21 may have a protective effect in patients with RA; on the other hand, serum FGF21 can be considered as a predictor of future decline in functional status and a potential marker for the progression of systemic inflammation in patients with RA. The prospects for using FGF21 for therapeutic purposes are assessed.
- 5 October 2025
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 40 (3) , 28-35
Open AccessThe value of fibroblast growth factor 21 in health and pathology
The article presents current ideas about the role of fibroblast growth factor 21 (FGF21) in the regulation of carbohydrate and lipid metabolism, as well as its contribution to the development of systemic inflammation in rheumatoid arthritis, both in laboratory animals and in humans. The classification of the fibroblast growth factor family, regulation of expression and receptor apparatus is considered. Positive effects of FGF21 have been noted in the form of normalization of carbohydrate and lipid metabolism, body weight; drugs analogues of FGF21 have proven themselves well as a therapeutic agent for the treatment of metabolic complications such as diabetes and fatty liver disease. At the same time, data are provided on the connection between elevated levels of FGF21 in blood serum and a number of pathological conditions, such as type 2 diabetes mellitus, coronary heart disease, obesity, non-alcoholic fatty liver disease, and end-stage renal failure. The facts about the controversial role of FGF21 against the background of systemic inflammation in patients with rheumatoid arthritis (RA) are reviewed. On the one hand, FGF21 may have a protective effect in patients with RA; on the other hand, serum FGF21 can be considered as a predictor of future decline in functional status and a potential marker for the progression of systemic inflammation in patients with RA. The prospects for using FGF21 for therapeutic purposes are assessed.
- 30 December 2024
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- Vol. 88 (4) , 9-12
Relationship between the level of antibodies to the RA-33 antigen and the course of rheumatoid arthritis
Objective: to study the relationship between the serum level of antibodies to the RA-33 antigen and the characteristics of the course of rheumatoid arthritis (RA). Materials and methods. The study included 88 patients with a diagnosis of RA that met the ACR/EULAR criteria, 2010. All observed study participants were women (n=100%), aged from 22 to 81 years (M ± σ, 54.3 ± 12.1 years). Rheumatoid factor was detected in 64 people (72.7%). 59 (67%) study participants were positive for anti-CCP. The duration of RA was 0.5–30 years (M ± σ, 11.2 ± 8.6 years), the degree of activity according to DAS28: 0 degree of activity – 19 (21.6%) patients, 1 degree – 10 (11.6%), 2 degree – 52 (59.1%), 3 degree of activity – 7 (7.7%) patients. Among the observed patients, individuals with III radiological stage of the disease predominated. Statistical processing was performed using the Statistica 12.5 software package for Windows. Results. The level of anti-RA-33 was assessed in a group of RA patients and healthy donors. The level anti-RA-33 was assessed in a group of RA patients and healthy donors. The level normal anti-RA-33 in healthy people, calculated as M±σ, was 10.3±10.2 U/ml (from 0.1 U/ml to 20.5 U/ml). The average level anti-RA-33 in RA patients, calculated as M±σ, was 12.7±31.6 U/ml (from 0 U/ml to 44.3 U/ml). The increase in the level anti-RA-33, compared with donors, is statistically significant (p=0.025) and was observed in 12.5% RA patients. Among 24 patients with RA seronegative by RF, an increase in the level anti-RA-33 was detected in 2 (8.3%) patients, and among 29 patients seronegative by ACCP - also in 2 (6.9%) patients. An increase in the level anti-RA-33 was mainly observed at the initial stages of the disease and with initial radiographic changes. In patients with an increased level anti-RA-33 (more than 20.5 U/ml), pronounced functional disorders were more often detected. Findings. Thus, it can be concluded that antibodies to anti-RA33 can potentially provide additional diagnostic value in RA. Keywords: rheumatoid arthritis, diagnostics of rheumatoid arthritis, antibodies to RA-33, heterogeneous nuclear ribonucleoprotein, HnRPA2B1.
- 30 December 2024
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- Vol. 88 (4) , 9-12
Relationship between the level of antibodies to the RA-33 antigen and the course of rheumatoid arthritis
Objective: to study the relationship between the serum level of antibodies to the RA-33 antigen and the characteristics of the course of rheumatoid arthritis (RA). Materials and methods. The study included 88 patients with a diagnosis of RA that met the ACR/EULAR criteria, 2010. All observed study participants were women (n=100%), aged from 22 to 81 years (M ± σ, 54.3 ± 12.1 years). Rheumatoid factor was detected in 64 people (72.7%). 59 (67%) study participants were positive for anti-CCP. The duration of RA was 0.5–30 years (M ± σ, 11.2 ± 8.6 years), the degree of activity according to DAS28: 0 degree of activity – 19 (21.6%) patients, 1 degree – 10 (11.6%), 2 degree – 52 (59.1%), 3 degree of activity – 7 (7.7%) patients. Among the observed patients, individuals with III radiological stage of the disease predominated. Statistical processing was performed using the Statistica 12.5 software package for Windows. Results. The level of anti-RA-33 was assessed in a group of RA patients and healthy donors. The level anti-RA-33 was assessed in a group of RA patients and healthy donors. The level normal anti-RA-33 in healthy people, calculated as M±σ, was 10.3±10.2 U/ml (from 0.1 U/ml to 20.5 U/ml). The average level anti-RA-33 in RA patients, calculated as M±σ, was 12.7±31.6 U/ml (from 0 U/ml to 44.3 U/ml). The increase in the level anti-RA-33, compared with donors, is statistically significant (p=0.025) and was observed in 12.5% RA patients. Among 24 patients with RA seronegative by RF, an increase in the level anti-RA-33 was detected in 2 (8.3%) patients, and among 29 patients seronegative by ACCP - also in 2 (6.9%) patients. An increase in the level anti-RA-33 was mainly observed at the initial stages of the disease and with initial radiographic changes. In patients with an increased level anti-RA-33 (more than 20.5 U/ml), pronounced functional disorders were more often detected. Findings. Thus, it can be concluded that antibodies to anti-RA33 can potentially provide additional diagnostic value in RA. Keywords: rheumatoid arthritis, diagnostics of rheumatoid arthritis, antibodies to RA-33, heterogeneous nuclear ribonucleoprotein, HnRPA2B1.
- 30 March 2024
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- Vol. 85 (1) , 33-36
Determination of antinuclear antibodies by immunoblotting to clarify the immunological characteristics of patients with systemic lupus erythematosus and Sjogren's syndrome
Objective: to study the immunological characteristics of patients with systemic lupus erythematosus and Sjogren's syndrome by determining antinuclear antibodies using immunoblotting. Materials and methods. We observed 69 patients whose average age was 38.9 years [23.2-62.9], of which 63 (91.30%) were women and 6 (8.69%) men. BMI was 27.3 kg/m2 [21.8-49.2]. Inclusion criteria: age from 18 to 70 years, presence of a reliable diagnosis. To study the diagnostic value of determining the ANA profile, patients were divided into 3 groups: 1st group – 15 patients with systemic lupus erythematosus (SLE), 2nd – 21 patients with the disease and Sjögren’s syndrome (SS), 3rd (control) group – 33 patients with osteoarthritis. The control group was comparable to the study groups by gender and age. Results. The determination of anti-SS-A in SLE has good quality (area under the ROC curve - 0.66). A cut-off value was determined with 79.6% specificity and 53.3% sensitivity. Anti-RNP/SM, anti-Sm, anti-dsDNA and anti-HI were somewhat less sensitive (30%), with a specificity level of 91% for anti-dsDNA and anti-Sm and 100% for anti-RNP/Sm and anti -HI. The most informative diagnostic tests for the disease and Sjogren's syndrome are anti-Ro-52 recombinant (sensitivity 57.1%, specificity 96%), anti-SS-Anative (sensitivity 52.4%, specificity 86%). The determination of anti-Ro-52 in SS is of good quality, which confirms the value of the area under the ROC curve (>0.7). The optimal cut-off value corresponded to 99.6% specificity and 57.1% sensitivity. Somewhat less sensitive (28.6%) were anti-Sm (specificity - 92%), anti-dsDNA (specificity - 92%) and anti-RIB (specificity 100.0%). Findings. The laboratory tests studied, as a rule, had high specificity, but rather low sensitivity. The most specific tests for diagnosing SLE are antibodies to the antigens RNP/Sm, SS-Anative, antibodies to histones, for SS - anti-SS-Anative, anti-Ro-52 recombinant, anti-RIB. Keywords: systemic lupus erythematosus, Sjögren's syndrome, immunoblotting, antinuclear antibodies.
- 30 March 2024
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- Vol. 85 (1) , 33-36
Determination of antinuclear antibodies by immunoblotting to clarify the immunological characteristics of patients with systemic lupus erythematosus and Sjogren's syndrome
Objective: to study the immunological characteristics of patients with systemic lupus erythematosus and Sjogren's syndrome by determining antinuclear antibodies using immunoblotting. Materials and methods. We observed 69 patients whose average age was 38.9 years [23.2-62.9], of which 63 (91.30%) were women and 6 (8.69%) men. BMI was 27.3 kg/m2 [21.8-49.2]. Inclusion criteria: age from 18 to 70 years, presence of a reliable diagnosis. To study the diagnostic value of determining the ANA profile, patients were divided into 3 groups: 1st group – 15 patients with systemic lupus erythematosus (SLE), 2nd – 21 patients with the disease and Sjögren’s syndrome (SS), 3rd (control) group – 33 patients with osteoarthritis. The control group was comparable to the study groups by gender and age. Results. The determination of anti-SS-A in SLE has good quality (area under the ROC curve - 0.66). A cut-off value was determined with 79.6% specificity and 53.3% sensitivity. Anti-RNP/SM, anti-Sm, anti-dsDNA and anti-HI were somewhat less sensitive (30%), with a specificity level of 91% for anti-dsDNA and anti-Sm and 100% for anti-RNP/Sm and anti -HI. The most informative diagnostic tests for the disease and Sjogren's syndrome are anti-Ro-52 recombinant (sensitivity 57.1%, specificity 96%), anti-SS-Anative (sensitivity 52.4%, specificity 86%). The determination of anti-Ro-52 in SS is of good quality, which confirms the value of the area under the ROC curve (>0.7). The optimal cut-off value corresponded to 99.6% specificity and 57.1% sensitivity. Somewhat less sensitive (28.6%) were anti-Sm (specificity - 92%), anti-dsDNA (specificity - 92%) and anti-RIB (specificity 100.0%). Findings. The laboratory tests studied, as a rule, had high specificity, but rather low sensitivity. The most specific tests for diagnosing SLE are antibodies to the antigens RNP/Sm, SS-Anative, antibodies to histones, for SS - anti-SS-Anative, anti-Ro-52 recombinant, anti-RIB. Keywords: systemic lupus erythematosus, Sjögren's syndrome, immunoblotting, antinuclear antibodies.
- 13 January 2024
- Published by Alfmed LLC in Medical alphabet
- No. 31,p. 46-50
Quality of life dynamics in patients with knee osteoarthritis on intra-articular therapy with bioactive concentrate of small sea fish and domestically produced sodium hyaluronate
Introduction. The quality of life in patients with osteoarthritis (OA) depends on the severity of functional disorders, pain syndrome and the efficacy of their pharmacological correction.Purpose of the study. To evaluate the dynamics of the life quality in patients with knee osteoarthritis treated with intra-articular injections of domestically produced sodium hyaluronate (synovial fluid prosthesis) or with bioactive concentrate of small sea fish (BACSSF).Materials and methods. 180 patients with knee osteoarthritis were examined. The study group consisted of 50 patients who received injections of sodium hyaluronate (prosthesis synovial fluid), intra-articularly. Comparison group included 30 patients treated with BACSSF 2 ml No. 5 intraarticularly. Control group consisted of 100 patients who received BACSSF intramuscularly 1 ml No. 20. Study design: duration 12 months with prospective monitoring of quality of life according to the SF-36 scale, six visits.Results. When included in the study, the level of physical and mental health components between the groups of patients differed statistically insignificantly (p = 0.369 and p = 0.089). According to the study results, used pharmacotherapy improved quality of life in all groups. However, the groups differed statistically significantly in the speed of achieving an analgesic effect, the severity of pain reduction and the duration of maintenance of the therapy effect. The best dynamics of the physical and mental components of health was in a group of patients with knee osteoarthritis treated with intra-articular sodium hyaluronate.Conclusions. In real clinical practice, it is not always possible to improve the quality of life of patients with knee osteoarthritis. Symptomatic delayed-release medications (SYSADOA) are effective in the early stages of the disease. The positive clinical effect of intra-articular therapy with sodium hyaluronate develops earlier and lasts longer than therapy with another SYSADOA (BACSSF).
- 13 January 2024
- Published by Alfmed LLC in Medical alphabet
- No. 31,p. 46-50
Quality of life dynamics in patients with knee osteoarthritis on intra-articular therapy with bioactive concentrate of small sea fish and domestically produced sodium hyaluronate
Introduction. The quality of life in patients with osteoarthritis (OA) depends on the severity of functional disorders, pain syndrome and the efficacy of their pharmacological correction.Purpose of the study. To evaluate the dynamics of the life quality in patients with knee osteoarthritis treated with intra-articular injections of domestically produced sodium hyaluronate (synovial fluid prosthesis) or with bioactive concentrate of small sea fish (BACSSF).Materials and methods. 180 patients with knee osteoarthritis were examined. The study group consisted of 50 patients who received injections of sodium hyaluronate (prosthesis synovial fluid), intra-articularly. Comparison group included 30 patients treated with BACSSF 2 ml No. 5 intraarticularly. Control group consisted of 100 patients who received BACSSF intramuscularly 1 ml No. 20. Study design: duration 12 months with prospective monitoring of quality of life according to the SF-36 scale, six visits.Results. When included in the study, the level of physical and mental health components between the groups of patients differed statistically insignificantly (p = 0.369 and p = 0.089). According to the study results, used pharmacotherapy improved quality of life in all groups. However, the groups differed statistically significantly in the speed of achieving an analgesic effect, the severity of pain reduction and the duration of maintenance of the therapy effect. The best dynamics of the physical and mental components of health was in a group of patients with knee osteoarthritis treated with intra-articular sodium hyaluronate.Conclusions. In real clinical practice, it is not always possible to improve the quality of life of patients with knee osteoarthritis. Symptomatic delayed-release medications (SYSADOA) are effective in the early stages of the disease. The positive clinical effect of intra-articular therapy with sodium hyaluronate develops earlier and lasts longer than therapy with another SYSADOA (BACSSF).
- Open Access
- 23 November 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 136-142
Association of serum chemerin levels with complications and comorbidity in rheumatoid arthritis
Introduction. Rheumatoid arthritis (RA) is a systemic autoimmune disease as well as a typical inflammatory process. Chemerin is a fat tissue cytokine, which specific receptors were discovered on the surface of the innate immune cells. It is of interest to study the association of chemerin with the complications and comorbidity in RA.Aim. To study the association between serum chemerin levels with complications and comorbidity in rheumatoid arthritis.Materials and methods. 88 women with RA were enrolled in our study. ll patients undergone standard clinical and laboratory examination. Serum chemerin, high-sensitive C-reactive protein (hsCRP), anti-citrullinated protein antibodies, insulin and C-peptide levels were determined using ELISA. X-ray absorptiometry was performed. Statistical analysis was performed using conventional methods with a software package Statistica 10.0.Results. Median chemerin concentration was 463.5 [366–576.5] ng/ml. Chemerin concentration correlated with the age (ρ = 0.232; р = 0.030), weight (ρ = 0.254; р = 0.017) and body mass index (BMI) (ρ = 0.212; р = 0.047), but wasn’t associated with the RA classification criteria. Positive correlation between chemerin concentration and number of painful joints (NPJ) (ρ = 0.213; р = 0.046) and hsCRP (ρ = 0.273; р = 0.010) was observed. Patients with type 2 diabetes mellitus (DM2) had higher chemerin concentration (598.0 ng/ml vs 479.5 ng/ml, Z = -2.68; p = 0.007) and patients with cholecystectomy in anamesis had lower (359.0 ng/ml vs 479.0 ng/ml, Z = 2.02; p = 0.043). Chemerin concentration correlated with systolic and diastolic blood pressure (BP) (ρ = -0.41; р < 0.001 and ρ = -0.27; р = 0.028, respectively).Conclusions. Chemerin concentration in women with RA correlates with age, weight, BMI, NPJ and hsCRP. Chemerin concentration in patients with comorbid DM2 was higher and in patients comorbid with cholecystectomy in anamnesis was lower. Chemerin concentration correlates negatively with a systolic and diastolic BP.
- 23 November 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 136-142
Open AccessAssociation of serum chemerin levels with complications and comorbidity in rheumatoid arthritis
Introduction. Rheumatoid arthritis (RA) is a systemic autoimmune disease as well as a typical inflammatory process. Chemerin is a fat tissue cytokine, which specific receptors were discovered on the surface of the innate immune cells. It is of interest to study the association of chemerin with the complications and comorbidity in RA.Aim. To study the association between serum chemerin levels with complications and comorbidity in rheumatoid arthritis.Materials and methods. 88 women with RA were enrolled in our study. ll patients undergone standard clinical and laboratory examination. Serum chemerin, high-sensitive C-reactive protein (hsCRP), anti-citrullinated protein antibodies, insulin and C-peptide levels were determined using ELISA. X-ray absorptiometry was performed. Statistical analysis was performed using conventional methods with a software package Statistica 10.0.Results. Median chemerin concentration was 463.5 [366–576.5] ng/ml. Chemerin concentration correlated with the age (ρ = 0.232; р = 0.030), weight (ρ = 0.254; р = 0.017) and body mass index (BMI) (ρ = 0.212; р = 0.047), but wasn’t associated with the RA classification criteria. Positive correlation between chemerin concentration and number of painful joints (NPJ) (ρ = 0.213; р = 0.046) and hsCRP (ρ = 0.273; р = 0.010) was observed. Patients with type 2 diabetes mellitus (DM2) had higher chemerin concentration (598.0 ng/ml vs 479.5 ng/ml, Z = -2.68; p = 0.007) and patients with cholecystectomy in anamesis had lower (359.0 ng/ml vs 479.0 ng/ml, Z = 2.02; p = 0.043). Chemerin concentration correlated with systolic and diastolic blood pressure (BP) (ρ = -0.41; р < 0.001 and ρ = -0.27; р = 0.028, respectively).Conclusions. Chemerin concentration in women with RA correlates with age, weight, BMI, NPJ and hsCRP. Chemerin concentration in patients with comorbid DM2 was higher and in patients comorbid with cholecystectomy in anamnesis was lower. Chemerin concentration correlates negatively with a systolic and diastolic BP.
- 30 September 2023
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- Vol. 83 (3) , 33-36
Relationship of the systemic level of chemerin and clinical - laboratory parameters in patients with rheumatoid arthritis
- 30 September 2023
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- Vol. 83 (3) , 33-36
Relationship of the systemic level of chemerin and clinical - laboratory parameters in patients with rheumatoid arthritis
- Open Access
- 19 August 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 166-174
Assessment of the quality of life of patients with gonarthrosis treated with a prosthesis of synovial fluid of domestic production
Introduction. Osteoarthritis (OA) is a chronic progressive disease of the joints, accompanied with pain, which limits the mobility of patients. Functional limitations, chronic pain syndrome worsen the quality of life (QoL) in OA of the joints of the lower extremities. QoL significantly depends on the effectiveness and methods of pain treatment, correction of functional disorders.Aim. Evaluation of the dynamics of QoL in patients with gonarthrosis treated with a high-tech synovial fluid prosthesis – sodium hyaluronate, domestic production.Materials and methods. The study group consisted of 50 patients who received intra-articular (IA) injections of domestically produced sodium hyaluronate (OOO Ingal, Russia). Comparison group – 30 patients treated with 2 ml of symptomatic drugs of delayed action (SYSADOA) (bioactive concentrate of small marine fish) administrated IA No. 5. Control group – 100 patients treated with a 1 ml of SYSADOA drugs administrated intramuscularly (IM) No. 20. Study program: 12 months, 6 visits with prospective monitoring of the quality of life of patients according to SF-36 compared with baseline data.Results. At the time of inclusion, patients had a similar level of physical and mental health components, which did not differ statistically significantly (p = 0.369 and p = 0.089). The study group demonstrated the best dynamics of the physical and mental components of health. The therapy was effective in all groups: most patients showed a statistically significant decrease in pain syndrome, an increase in QoL. The groups differed significantly in the speed of achieving the effect of pain relief, the severity of pain reduction and the duration of the effect of treatment.Conclusions. The spectrum of side effects of non-steroidal anti-inflammatory drugs (NSAIDs) does not allow their use for pain relief indefinitely. SYSADOAs become less effective in the progression of OA than in the early stages of the disease. The positive clinical effect of intra-articular injection of sodium hyaluronate solutions occurs faster and lasts longer than when using SYSADOA.
- 19 August 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 166-174
Open AccessAssessment of the quality of life of patients with gonarthrosis treated with a prosthesis of synovial fluid of domestic production
Introduction. Osteoarthritis (OA) is a chronic progressive disease of the joints, accompanied with pain, which limits the mobility of patients. Functional limitations, chronic pain syndrome worsen the quality of life (QoL) in OA of the joints of the lower extremities. QoL significantly depends on the effectiveness and methods of pain treatment, correction of functional disorders.Aim. Evaluation of the dynamics of QoL in patients with gonarthrosis treated with a high-tech synovial fluid prosthesis – sodium hyaluronate, domestic production.Materials and methods. The study group consisted of 50 patients who received intra-articular (IA) injections of domestically produced sodium hyaluronate (OOO Ingal, Russia). Comparison group – 30 patients treated with 2 ml of symptomatic drugs of delayed action (SYSADOA) (bioactive concentrate of small marine fish) administrated IA No. 5. Control group – 100 patients treated with a 1 ml of SYSADOA drugs administrated intramuscularly (IM) No. 20. Study program: 12 months, 6 visits with prospective monitoring of the quality of life of patients according to SF-36 compared with baseline data.Results. At the time of inclusion, patients had a similar level of physical and mental health components, which did not differ statistically significantly (p = 0.369 and p = 0.089). The study group demonstrated the best dynamics of the physical and mental components of health. The therapy was effective in all groups: most patients showed a statistically significant decrease in pain syndrome, an increase in QoL. The groups differed significantly in the speed of achieving the effect of pain relief, the severity of pain reduction and the duration of the effect of treatment.Conclusions. The spectrum of side effects of non-steroidal anti-inflammatory drugs (NSAIDs) does not allow their use for pain relief indefinitely. SYSADOAs become less effective in the progression of OA than in the early stages of the disease. The positive clinical effect of intra-articular injection of sodium hyaluronate solutions occurs faster and lasts longer than when using SYSADOA.